New genetics findings unravel key components of fracture risk in osteoporosis

August 29, 2018

The largest study ever to investigate the genetics of osteoporosis and fracture risk determined that only two examined factors - bone mineral density (BMD) and muscle strength - play a potentially causal role in the risk of suffering osteoporotic fracture, a major health problem affecting more than 9 million people worldwide very year. Other clinical risk factors like vitamin D levels and calcium intake, historically considered to be crucial mediators of fracture, were not found to directly predispose people in the general population to fracture. This research was published in the BMJ.

"These findings suggest that interventions aimed at increasing bone strength are more likely to prevent fractures than widespread supplementation with vitamin D," said Dr. Brent Richards, a genetic epidemiologist at the Lady Davis Institute at the Jewish General Hospital and Professor of Medicine at McGill University, and one of the senior investigators on the paper. "Our study, the first genome-wide association study for fracture risk, has provided important insight on the biologic mechanisms leading to fracture and how to prevent it."

An international team of researchers collaborated to examine data from 185,057 cases and 377,201 controls part of the Genetic Factors of Osteoporosis (GEFOS) Consortium, the UKBiobank Study and the 23andMe biotech company. The study was co-led by researchers from McGill University and the Erasmus University Medical Center in Rotterdam, The Netherlands.

"Our research confirms that BMD is the most important determinant of fracture risk and that prevention strategies aimed at increasing or maintaining bone density are the most likely to be successful," Dr. Richards pointed out. "One of the most important aspects of this research is the robust evidence showing that vitamin D supplementation in the general population is unlikely to be effective for the prevention of fracture. This will encourage clinicians to focus patients on building bone density as a more effective preventive measure against fracture."

The researchers came to these conclusions by demonstrating that the genetic factors that lead to lowered vitamin D levels in the general population do not increase risk of fracture.

Approximately 30% of people over the age of sixty-five take Vitamin D supplements partly because clinical guidelines for osteoporosis management and fracture prevention suggest such supplements. However, recent large randomized controlled clinical trials have failed to confirm any benefit of vitamin D supplementation in patients without pronounced deficiency of these factors. Thus, these findings and those derived from this study highlight the need to re-assess its wide-spread use in clinical practice.

The authors do caution that patients using osteoporosis medication should not discontinue their supplements before consulting with their treating physicians. Maintaining a healthy diet, remaining physically active, and fifteen minutes of sun exposure everyday are the main pillars of a sustainable bone health. These results do also not apply to individuals with low vitamin D levels.
-end-
For media inquiries, and to arrange interviews with Dr. Richards contact:

Tod Hoffman
Research Communications Officer
Lady Davis Institute
Tel.: 514-340-8222 x 28661
Email: tod.hoffman@ladydavis.ca

For more about the Lady Davis Institute: http://www.ladydavis.ca

For more about the Jewish General Hospital: http://www.jgh.ca

McGill University

Related Osteoporosis Articles from Brightsurf:

New opportunities for detecting osteoporosis
Osteoporosis can be detected through low dose computed tomography (LDCT) imaging tests performed for lung cancer screening or other purposes.

Oxytocin can help prevent osteoporosis
In a laboratory experiment with rats, Brazilian researchers succeeded in reversing natural processes associated with aging that lead to loss of bone density and strength.

New strategy against osteoporosis
An international research team has found a new approach that may be able to reduce bone loss in osteoporosis and maintain bone health.

New review on management of osteoporosis in premenopausal women
An IOF and ECTS Working Group have published an updated review of literature published after 2017 on premenopausal osteoporosis.

Cardiac CT can double as osteoporosis test
Cardiac CT exams performed to assess heart health also provide an effective way to screen for osteoporosis, potentially speeding treatment to the previously undiagnosed, according to a new study.

Osteoporosis treatment may also protect against pneumonia
A recent study published in the Journal of Bone and Mineral Research found that nitrogen-containing bisphosphonates (N-BPs) such as alendronate, which are widely used to treat postmenopausal osteoporosis, are linked with lower risks of pneumonia and of dying from pneumonia.

New pharmaceutical target reverses osteoporosis in mice
Biomedical engineers at Duke University have discovered that an adenosine receptor called A2B can be pharmaceutically activated to reverse bone degradation caused by osteoporosis in mouse models of the disease.

A link between mitochondrial damage and osteoporosis
In healthy people, a tightly controlled process balances out the activity of osteoblasts, which build bone, and osteoclasts, which break it down.

Many stroke patients not screened for osteoporosis, despite known risks
Many stroke survivors have an increased risk of osteoporosis, falls or breaks when compared to healthy people.

Many postmenopausal women do not receive treatment for osteoporosis
The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society.

Read More: Osteoporosis News and Osteoporosis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.